drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00641 | DB09280 | 467 | 1,604 | [
"DDInter1675",
"DDInter1101"
] | Simvastatin | Lumacaftor | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
467,
25,
1604
]
],
[
[
467,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
467,
24,
671
],
[
671,
24,
1604
]
],
[
[
467,
63,
522
],
[
522,
... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluva... |
DB00439 | DB08904 | 289 | 375 | [
"DDInter341",
"DDInter342"
] | Cerivastatin | Certolizumab pegol | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
289,
24,
375
]
],
[
[
289,
24,
1047
],
[
1047,
24,
375
]
],
[
[
289,
24,
1434
],
[
1434,
63,
375
]
],
[
[
289,
63,
10
],
[
10,
2... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emt... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Cerivastatin may cause a moderate interaction that could exacerbate diseases whe... |
DB00285 | DB01211 | 1,100 | 609 | [
"DDInter1927",
"DDInter393"
] | Venlafaxine | Clarithromycin | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1100,
24,
609
]
],
[
[
1100,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1100,
21,
28879
],
[
28879,
60,
609
]
],
[
[
1100,
63,
600
],
[
600,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Venlafaxine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Venlafaxine (Compound) causes Gingival bleeding (Side Effect) and Gingival bleeding (Side Effect) is caused by Clarithromycin (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00549 | DB06674 | 522 | 908 | [
"DDInter1955",
"DDInter837"
] | Zafirlukast | Golimumab | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
522,
24,
908
]
],
[
[
522,
63,
268
],
[
268,
24,
908
]
],
[
[
522,
24,
505
],
[
505,
63,
908
]
],
[
[
522,
24,
458
],
[
458,
24,... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01155 | DB13074 | 872 | 877 | [
"DDInter813",
"DDInter1110"
] | Gemifloxacin | Macimorelin | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
872,
25,
877
]
],
[
[
872,
62,
112
],
[
112,
23,
877
]
],
[
[
872,
63,
1479
],
[
1479,
24,
877
]
],
[
[
872,
24,
913
],
[
913,
2... | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicyli... |
DB00083 | DB00771 | 677 | 262 | [
"DDInter225",
"DDInter397"
] | Botulinum toxin type A | Clidinium | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
677,
24,
262
]
],
[
[
677,
24,
1511
],
[
1511,
63,
262
]
],
[
[
677,
24,
19
],
[
19,
24,
262
]
],
[
[
677,
24,
352
],
[
352,
35,... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepe... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00604 | DB01100 | 1,425 | 1,568 | [
"DDInter385",
"DDInter1470"
] | Cisapride | Pimozide | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
1425,
25,
1568
]
],
[
[
1425,
64,
78
],
[
78,
40,
1568
]
],
[
[
1425,
6,
4228
],
[
4228,
45,
1568
]
],
[
[
1425,
18,
2976
],
[
2976,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} (Comp... | Cisapride may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Cisapride (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Pimozide (Compound)
Cisapride (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Pimo... |
DB06595 | DB08908 | 1,491 | 713 | [
"DDInter1214",
"DDInter564"
] | Midostaurin | Dimethyl fumarate | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
1491,
24,
713
]
],
[
[
1491,
25,
996
],
[
996,
24,
713
]
],
[
[
1491,
63,
4
],
[
4,
24,
713
]
],
[
[
1491,
24,
594
],
[
594,
24,... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
],
[
"... | Midostaurin may lead to a major life threatening interaction when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate... |
DB11757 | DB12500 | 960 | 283 | [
"DDInter994",
"DDInter714"
] | Istradefylline | Fedratinib | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
960,
24,
283
]
],
[
[
960,
63,
351
],
[
351,
23,
283
]
],
[
[
960,
63,
1419
],
[
1419,
24,
283
]
],
[
[
960,
24,
971
],
[
971,
2... | [
[
[
"Istradefylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Istradefylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Im... |
DB00461 | DB01191 | 598 | 1,039 | [
"DDInter1254",
"DDInter518"
] | Nabumetone | Dexfenfluramine | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
598,
24,
1039
]
],
[
[
598,
6,
7950
],
[
7950,
45,
1039
]
],
[
[
598,
24,
1046
],
[
1046,
63,
1039
]
],
[
[
598,
25,
500
],
[
500,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Nabumetone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Nabumetone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexfenfluramine (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Nabu... |
DB00363 | DB01211 | 695 | 609 | [
"DDInter419",
"DDInter393"
] | Clozapine | Clarithromycin | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
695,
24,
609
]
],
[
[
695,
6,
4973
],
[
4973,
45,
609
]
],
[
[
695,
7,
16703
],
[
16703,
46,
609
]
],
[
[
695,
18,
4884
],
[
4884,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Clozapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Clozapine (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Clarithromycin (Compound)
Clozapine (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Clarithromycin (Compound)
C... |
DB00222 | DB00562 | 245 | 1,014 | [
"DDInter825",
"DDInter188"
] | Glimepiride | Benzthiazide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Moderate | 1 | [
[
[
245,
24,
1014
]
],
[
[
245,
24,
811
],
[
811,
40,
1014
]
],
[
[
245,
24,
674
],
[
674,
1,
1014
]
],
[
[
245,
24,
126
],
[
126,
6... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Be... |
DB01244 | DB09078 | 762 | 1,228 | [
"DDInter192",
"DDInter1036"
] | Bepridil | Lenvatinib | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
762,
25,
1228
]
],
[
[
762,
62,
112
],
[
112,
23,
1228
]
],
[
[
762,
64,
609
],
[
609,
24,
1228
]
],
[
[
762,
63,
770
],
[
770,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole... | Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Bepridil may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may ... |
DB00099 | DB13007 | 440 | 1,060 | [
"DDInter735",
"DDInter642"
] | Filgrastim | Enfortumab vedotin | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
440,
24,
1060
]
],
[
[
440,
24,
350
],
[
350,
24,
1060
]
],
[
[
440,
63,
268
],
[
268,
24,
1060
]
],
[
[
440,
25,
1064
],
[
1064,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginterfer... |
DB00222 | DB06788 | 245 | 1,616 | [
"DDInter825",
"DDInter864"
] | Glimepiride | Histrelin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
245,
24,
1616
]
],
[
[
245,
24,
1247
],
[
1247,
23,
1616
]
],
[
[
245,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
245,
63,
1179
],
[
1179,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Risperidon... |
DB00169 | DB01324 | 386 | 178 | [
"DDInter367",
"DDInter1490"
] | Cholecalciferol | Polythiazide | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
386,
24,
178
]
],
[
[
386,
24,
674
],
[
674,
40,
178
]
],
[
[
386,
75,
1331
],
[
1331,
24,
178
]
],
[
[
386,
24,
286
],
[
286,
6... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiaz... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Cholecalciferol (Compound) resembles Ergocalciferol (Compound) and Cholecalciferol may lead to a major life threatening interaction when ... |
DB00865 | DB06292 | 939 | 549 | [
"DDInter187",
"DDInter474"
] | Benzphetamine | Dapagliflozin | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
939,
24,
549
]
],
[
[
939,
24,
1344
],
[
1344,
40,
549
]
],
[
[
939,
6,
8374
],
[
8374,
45,
549
]
],
[
[
939,
21,
28762
],
[
28762,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Benzphetamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Benzphetamine (Compound) causes Headache (Side E... |
DB00701 | DB00877 | 1,091 | 629 | [
"DDInter90",
"DDInter1678"
] | Amprenavir | Sirolimus | Amprenavir is a protease inhibitor used to treat HIV infection. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
1091,
25,
629
]
],
[
[
1091,
6,
4973
],
[
4973,
45,
629
]
],
[
[
1091,
21,
29203
],
[
29203,
60,
629
]
],
[
[
1091,
25,
1476
],
[
1476... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"... | Amprenavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Amprenavir (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Amprenavir may lead to a major life threatening interaction ... |
DB00652 | DB01575 | 234 | 1,054 | [
"DDInter1421",
"DDInter1005"
] | Pentazocine | Kaolin | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
234,
24,
1054
]
],
[
[
234,
25,
407
],
[
407,
63,
1054
]
],
[
[
234,
63,
85
],
[
85,
24,
1054
]
],
[
[
234,
24,
1123
],
[
1123,
... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Pentazocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u... | Pentazocine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate inter... |
DB00356 | DB01233 | 1,315 | 1,311 | [
"DDInter366",
"DDInter1197"
] | Chlorzoxazone | Metoclopramide | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1315,
24,
1311
]
],
[
[
1315,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
1315,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1315,
24,
649
],
[
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorzoxazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (C... | Chlorzoxazone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Chlorzoxazone (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00773 | DB12674 | 896 | 975 | [
"DDInter702",
"DDInter1105"
] | Etoposide | Lurbinectedin | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
896,
24,
975
]
],
[
[
896,
24,
1488
],
[
1488,
24,
975
]
],
[
[
896,
24,
159
],
[
159,
63,
975
]
],
[
[
896,
63,
372
],
[
372,
2... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and ... |
DB08816 | DB09039 | 578 | 1,670 | [
"DDInter1802",
"DDInter629"
] | Ticagrelor | Eliglustat | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
578,
24,
1670
]
],
[
[
578,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
578,
63,
121
],
[
121,
24,
1670
]
],
[
[
578,
64,
1409
],
[
1409,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenflurami... |
DB00759 | DB01575 | 1,620 | 1,054 | [
"DDInter1783",
"DDInter1005"
] | Tetracycline | Kaolin | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
1620,
24,
1054
]
],
[
[
1620,
1,
964
],
[
964,
24,
1054
]
],
[
[
1620,
63,
1252
],
[
1252,
24,
1054
]
],
[
[
1620,
24,
1482
],
[
1482,... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Tetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moder... | Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exa... |
DB09054 | DB09065 | 384 | 760 | [
"DDInter905",
"DDInter424"
] | Idelalisib | Cobicistat | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
384,
24,
760
]
],
[
[
384,
62,
479
],
[
479,
23,
760
]
],
[
[
384,
23,
1627
],
[
1627,
23,
760
]
],
[
[
384,
63,
1204
],
[
1204,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Idelalisib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol m... |
DB00757 | DB01021 | 1,166 | 674 | [
"DDInter581",
"DDInter1861"
] | Dolasetron | Trichlormethiazide | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Major | 2 | [
[
[
1166,
25,
674
]
],
[
[
1166,
64,
1014
],
[
1014,
40,
674
]
],
[
[
1166,
25,
178
],
[
178,
1,
674
]
],
[
[
1166,
25,
359
],
[
359,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
... | Dolasetron may lead to a major life threatening interaction when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Polythiazide and Polythiazide (Compound) resembles Trichlormethiazide (Compound)
Dolase... |
DB01067 | DB06791 | 959 | 1,446 | [
"DDInter826",
"DDInter1021"
] | Glipizide | Lanreotide | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
959,
24,
1446
]
],
[
[
959,
24,
154
],
[
154,
63,
1446
]
],
[
[
959,
63,
887
],
[
887,
24,
1446
]
],
[
[
959,
24,
655
],
[
655,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol m... |
DB00635 | DB15699 | 1,573 | 652 | [
"DDInter1515",
"DDInter232"
] | Prednisone | Brexucabtagene autoleucel | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
1573,
25,
652
]
],
[
[
1573,
24,
259
],
[
259,
24,
652
]
],
[
[
1573,
63,
1184
],
[
1184,
24,
652
]
],
[
[
1573,
25,
976
],
[
976,
... | [
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Anakin... |
DB12010 | DB15982 | 214 | 1,339 | [
"DDInter785",
"DDInter193"
] | Fostamatinib | Berotralstat | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
214,
25,
1339
]
],
[
[
214,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
214,
63,
761
],
[
761,
24,
1339
]
],
[
[
214,
24,
971
],
[
971,
... | [
[
[
"Fostamatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and S... |
DB00011 | DB01394 | 1,451 | 1,554 | [
"DDInter944",
"DDInter431"
] | Interferon alfa-n1 | Colchicine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
1451,
24,
1554
]
],
[
[
1451,
24,
367
],
[
367,
24,
1554
]
],
[
[
1451,
24,
375
],
[
375,
63,
1554
]
],
[
[
1451,
63,
1057
],
[
1057,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon ... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Colchicine
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases w... |
DB00501 | DB00712 | 752 | 1,274 | [
"DDInter380",
"DDInter763"
] | Cimetidine | Flurbiprofen | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Minor | 0 | [
[
[
752,
23,
1274
]
],
[
[
752,
63,
1119
],
[
1119,
1,
1274
]
],
[
[
752,
23,
935
],
[
935,
63,
1274
]
],
[
[
752,
24,
1523
],
[
1523,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Flurbiprofen (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ketoprofen and Ketoprofen may cause a moderate interactio... |
DB00370 | DB00983 | 1,251 | 480 | [
"DDInter1230",
"DDInter776"
] | Mirtazapine | Formoterol | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1251,
24,
480
]
],
[
[
1251,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1251,
6,
1704
],
[
1704,
45,
480
]
],
[
[
1251,
21,
28963
],
[
28963... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Mirtazapine (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound)
Mirtazapine (C... |
DB00341 | DB00996 | 1,242 | 1,198 | [
"DDInter343",
"DDInter791"
] | Cetirizine | Gabapentin | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Moderate | 1 | [
[
[
1242,
24,
1198
]
],
[
[
1242,
7,
2384
],
[
2384,
46,
1198
]
],
[
[
1242,
18,
10780
],
[
10780,
57,
1198
]
],
[
[
1242,
21,
29600
],
[
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Cetirizine",
"{u} (Compound) upregulates {v} (Gene)",
"CDK6"
],
[
"CDK6",
"{u} (Gene) is upregulated by {v} (Com... | Cetirizine (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Gabapentin (Compound)
Cetirizine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Gabapentin (Compound)
Cetirizine (Compound) causes Seborrhoeic dermatitis (Side Effect) and Seborrhoeic dermatitis (Side Effect) is ... |
DB00851 | DB00853 | 611 | 1,686 | [
"DDInter463",
"DDInter1762"
] | Dacarbazine | Temozolomide | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
611,
24,
1686
]
],
[
[
611,
5,
11556
],
[
11556,
44,
1686
]
],
[
[
611,
54,
19138
],
[
19138,
15,
1686
]
],
[
[
611,
23,
945
],
[
945,... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Dacarbazine",
"{u} (Compound) treats {v} (Disease)",
"melanoma"
],
[
"melanoma",
"{u} (Disease) is treated by... | Dacarbazine (Compound) treats melanoma (Disease) and melanoma (Disease) is treated by Temozolomide (Compound)
Dacarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Temozolomide (Compound)
Dacarbazine may cause a minor interaction that can ... |
DB00357 | DB00570 | 1,051 | 147 | [
"DDInter71",
"DDInter1936"
] | Aminoglutethimide | Vinblastine | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
1051,
24,
147
]
],
[
[
1051,
24,
134
],
[
134,
24,
147
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
147
]
],
[
[
1051,
21,
28658
],
[
28658,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vinblastine (Compound)
... |
DB00283 | DB00477 | 701 | 216 | [
"DDInter395",
"DDInter363"
] | Clemastine | Chlorpromazine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
701,
24,
216
]
],
[
[
701,
24,
1178
],
[
1178,
1,
216
]
],
[
[
701,
24,
902
],
[
902,
40,
216
]
],
[
[
701,
24,
662
],
[
662,
63... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Chlorpromazi... |
DB01208 | DB01309 | 945 | 1,254 | [
"DDInter1705",
"DDInter933"
] | Sparfloxacin | Insulin glulisine | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Major | 2 | [
[
[
945,
25,
1254
]
],
[
[
945,
64,
1424
],
[
1424,
24,
1254
]
],
[
[
945,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
945,
25,
1220
],
[
1220,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"... | Sparfloxacin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cau... |
DB08893 | DB09098 | 271 | 98 | [
"DDInter1229",
"DDInter1700"
] | Mirabegron | Somatrem | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Minor | 0 | [
[
[
271,
23,
98
]
],
[
[
271,
23,
159
],
[
159,
63,
98
]
],
[
[
271,
62,
609
],
[
609,
24,
98
]
],
[
[
271,
24,
124
],
[
124,
63,
... | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Cl... |
DB01229 | DB12130 | 973 | 1,017 | [
"DDInter1378",
"DDInter1094"
] | Paclitaxel (protein-bound) | Lorlatinib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
973,
24,
1017
]
],
[
[
973,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
973,
25,
976
],
[
976,
24,
1017
]
],
[
[
973,
24,
1554
],
[
1554,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Paclitaxel m... |
DB01242 | DB06081 | 1,237 | 1,046 | [
"DDInter410",
"DDInter286"
] | Clomipramine | Caplacizumab | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
1237,
24,
1046
]
],
[
[
1237,
64,
1039
],
[
1039,
24,
1046
]
],
[
[
1237,
63,
885
],
[
885,
24,
1046
]
],
[
[
1237,
63,
1479
],
[
1479... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
... | Clomipramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epo... |
DB00553 | DB00827 | 92 | 646 | [
"DDInter1177",
"DDInter383"
] | Methoxsalen | Cinoxacin | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Moderate | 1 | [
[
[
92,
24,
646
]
],
[
[
92,
21,
28722
],
[
28722,
60,
646
]
],
[
[
92,
24,
1274
],
[
1274,
24,
646
]
],
[
[
92,
24,
848
],
[
848,
6... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Methoxsalen",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by... | Methoxsalen (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cinoxacin (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cinoxaci... |
DB00092 | DB00563 | 58 | 663 | [
"DDInter40",
"DDInter1174"
] | Alefacept | Methotrexate | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
58,
24,
663
]
],
[
[
58,
24,
328
],
[
328,
62,
663
]
],
[
[
58,
24,
738
],
[
738,
63,
663
]
],
[
[
58,
63,
1648
],
[
1648,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and N... |
DB00738 | DB08913 | 485 | 1,186 | [
"DDInter1420",
"DDInter1561"
] | Pentamidine | Radium Ra 223 dichloride | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
485,
24,
1186
]
],
[
[
485,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
485,
24,
1491
],
[
1491,
24,
1186
]
],
[
[
485,
24,
1619
],
[
1619... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Pentamidine",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{... | Pentamidine (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseas... |
DB11853 | DB12267 | 230 | 1,476 | [
"DDInter1577",
"DDInter233"
] | Relugolix | Brigatinib | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Minor | 0 | [
[
[
230,
23,
1476
]
],
[
[
230,
63,
79
],
[
79,
24,
1476
]
],
[
[
230,
64,
478
],
[
478,
24,
1476
]
],
[
[
230,
25,
982
],
[
982,
63... | [
[
[
"Relugolix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Relugolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"... | Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Relugolix may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a mode... |
DB00382 | DB01142 | 62 | 1,264 | [
"DDInter1734",
"DDInter593"
] | Tacrine | Doxepin | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
62,
24,
1264
]
],
[
[
62,
24,
401
],
[
401,
24,
1264
]
],
[
[
62,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
62,
24,
112
],
[
112,
23... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Pr... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine ... |
DB00467 | DB00912 | 1,467 | 473 | [
"DDInter644",
"DDInter1581"
] | Enoxacin | Repaglinide | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Major | 2 | [
[
[
1467,
25,
473
]
],
[
[
1467,
24,
1512
],
[
1512,
24,
473
]
],
[
[
1467,
63,
1645
],
[
1645,
24,
473
]
],
[
[
1467,
24,
433
],
[
433,
... | [
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Repaglinide"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
... | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin ... |
DB01136 | DB08868 | 772 | 1,011 | [
"DDInter305",
"DDInter737"
] | Carvedilol | Fingolimod | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
772,
25,
1011
]
],
[
[
772,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
772,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
772,
23,
578
],
[
578,... | [
[
[
"Carvedilol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Carvedilol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingoli... | Carvedilol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Carvedilol (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor ... |
DB00163 | DB00928 | 1,461 | 1,426 | [
"DDInter1943",
"DDInter148"
] | Vitamin E | Azacitidine | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Moderate | 1 | [
[
[
1461,
24,
1426
]
],
[
[
1461,
24,
372
],
[
372,
1,
1426
]
],
[
[
1461,
24,
1064
],
[
1064,
25,
1426
]
],
[
[
1461,
24,
1488
],
[
1488,... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Azacitidine (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening inter... |
DB00153 | DB00418 | 1,331 | 536 | [
"DDInter662",
"DDInter1650"
] | Ergocalciferol | Secobarbital | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Moderate | 1 | [
[
[
1331,
24,
536
]
],
[
[
1331,
24,
1023
],
[
1023,
1,
536
]
],
[
[
1331,
21,
28722
],
[
28722,
60,
536
]
],
[
[
1331,
23,
752
],
[
752,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound)
Ergocalciferol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Secobarbital (Compound)
Ergocalciferol may cause a minor... |
DB00372 | DB00476 | 999 | 109 | [
"DDInter1793",
"DDInter608"
] | Thiethylperazine | Duloxetine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
999,
24,
109
]
],
[
[
999,
24,
758
],
[
758,
1,
109
]
],
[
[
999,
63,
1302
],
[
1302,
1,
109
]
],
[
[
999,
23,
286
],
[
286,
62,... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Dulo... |
DB00860 | DB13074 | 891 | 877 | [
"DDInter1513",
"DDInter1110"
] | Prednisolone | Macimorelin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
891,
24,
877
]
],
[
[
891,
63,
1020
],
[
1020,
24,
877
]
],
[
[
891,
24,
1479
],
[
1479,
24,
877
]
],
[
[
891,
1,
1486
],
[
1486,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic ac... |
DB01591 | DB09065 | 667 | 760 | [
"DDInter1696",
"DDInter424"
] | Solifenacin | Cobicistat | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
667,
25,
760
]
],
[
[
667,
63,
1101
],
[
1101,
23,
760
]
],
[
[
667,
24,
1374
],
[
1374,
23,
760
]
],
[
[
667,
63,
723
],
[
723,
... | [
[
[
"Solifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abira... |
DB09043 | DB12015 | 135 | 1,033 | [
"DDInter36",
"DDInter53"
] | Albiglutide | Alpelisib | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
135,
24,
1033
]
],
[
[
135,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
135,
62,
467
],
[
467,
24,
1033
]
],
[
[
135,
64,
1101
],
[
1101,
... | [
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Albiglutide may cause a minor interaction that can limit clinical effects when taken with Simvasta... |
DB01132 | DB01174 | 1,130 | 697 | [
"DDInter1472",
"DDInter1442"
] | Pioglitazone | Phenobarbital | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
1130,
24,
697
]
],
[
[
1130,
63,
759
],
[
759,
1,
697
]
],
[
[
1130,
6,
6017
],
[
6017,
45,
697
]
],
[
[
1130,
21,
28667
],
[
28667,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Pioglitazone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Phenobarbital (Compound)
Pioglitazone (Compound) causes Congenital anomaly (Side Ef... |
DB00041 | DB01136 | 1,648 | 772 | [
"DDInter38",
"DDInter305"
] | Aldesleukin | Carvedilol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1648,
24,
772
]
],
[
[
1648,
24,
475
],
[
475,
24,
772
]
],
[
[
1648,
24,
777
],
[
777,
63,
772
]
],
[
[
1648,
25,
770
],
[
770,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide... |
DB00472 | DB08816 | 758 | 578 | [
"DDInter758",
"DDInter1802"
] | Fluoxetine | Ticagrelor | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
758,
24,
578
]
],
[
[
758,
6,
4973
],
[
4973,
45,
578
]
],
[
[
758,
21,
28646
],
[
28646,
60,
578
]
],
[
[
758,
25,
1011
],
[
1011,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluoxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Fluoxetine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Fluoxetine may lead to a m... |
DB00196 | DB00497 | 600 | 828 | [
"DDInter743",
"DDInter1366"
] | Fluconazole | Oxycodone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Major | 2 | [
[
[
600,
25,
828
]
],
[
[
600,
24,
267
],
[
267,
64,
828
]
],
[
[
600,
24,
1516
],
[
1516,
1,
828
]
],
[
[
600,
6,
8374
],
[
8374,
4... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexon... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may lead to a major life threatening interaction when taken with Oxycodone
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Galantamine and Galantamine (Compou... |
DB00757 | DB00983 | 1,166 | 480 | [
"DDInter581",
"DDInter776"
] | Dolasetron | Formoterol | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1166,
24,
480
]
],
[
[
1166,
25,
1148
],
[
1148,
63,
480
]
],
[
[
1166,
64,
1523
],
[
1523,
25,
480
]
],
[
[
1166,
6,
6017
],
[
6017,
... | [
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprena... | Dolasetron may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Dolasetron may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major lif... |
DB01124 | DB09128 | 1,411 | 1,241 | [
"DDInter1828",
"DDInter231"
] | Tolbutamide | Brexpiprazole | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1411,
24,
1241
]
],
[
[
1411,
24,
549
],
[
549,
24,
1241
]
],
[
[
1411,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
1411,
63,
1179
],
[
1179... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin de... |
DB01229 | DB08880 | 973 | 1,510 | [
"DDInter1378",
"DDInter1771"
] | Paclitaxel (protein-bound) | Teriflunomide | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
973,
25,
1510
]
],
[
[
973,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
973,
24,
129
],
[
129,
63,
1510
]
],
[
[
973,
24,
1136
],
[
1136,
... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Paclitaxel may lead to a major life threatening interaction when taken with Teriflunomide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Paclitaxel may cause a ... |
DB00095 | DB01033 | 66 | 328 | [
"DDInter623",
"DDInter1156"
] | Efalizumab | Mercaptopurine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
66,
24,
328
]
],
[
[
66,
24,
663
],
[
663,
23,
328
]
],
[
[
66,
24,
384
],
[
384,
63,
328
]
],
[
[
66,
24,
134
],
[
134,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and ... |
DB09049 | DB11613 | 1,135 | 1,519 | [
"DDInter1261",
"DDInter1924"
] | Naloxegol | Velpatasvir | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Minor | 0 | [
[
[
1135,
23,
1519
]
],
[
[
1135,
62,
1374
],
[
1374,
24,
1519
]
],
[
[
1135,
25,
384
],
[
384,
24,
1519
]
],
[
[
1135,
24,
98
],
[
98,
... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Velpatasvir"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Naloxegol may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a... |
DB00215 | DB01309 | 1,230 | 1,254 | [
"DDInter388",
"DDInter933"
] | Citalopram | Insulin glulisine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1230,
24,
1254
]
],
[
[
1230,
25,
1424
],
[
1424,
24,
1254
]
],
[
[
1230,
24,
480
],
[
480,
24,
1254
]
],
[
[
1230,
64,
73
],
[
73,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinin... | Citalopram may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause... |
DB01075 | DB01219 | 1,376 | 716 | [
"DDInter569",
"DDInter473"
] | Diphenhydramine | Dantrolene | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
1376,
24,
716
]
],
[
[
1376,
21,
28698
],
[
28698,
60,
716
]
],
[
[
1376,
24,
1609
],
[
1609,
63,
716
]
],
[
[
1376,
74,
100
],
[
100,... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect)... | Diphenhydramine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dantrolene (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when take... |
DB01066 | DB01377 | 1,462 | 1,283 | [
"DDInter316",
"DDInter1119"
] | Cefditoren | Magnesium oxide | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1462,
24,
1283
]
],
[
[
1462,
63,
1194
],
[
1194,
23,
1283
]
],
[
[
1462,
1,
1024
],
[
1024,
63,
1283
]
],
[
[
1462,
24,
286
],
[
286,... | [
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
... | Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Cefditoren (Compound) resembles Cefpodoxime (Compound) and Cefpodoxime may cause a moderate interaction that ... |
DB00026 | DB01320 | 1,184 | 651 | [
"DDInter94",
"DDInter783"
] | Anakinra | Fosphenytoin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
1184,
24,
651
]
],
[
[
1184,
24,
362
],
[
362,
1,
651
]
],
[
[
1184,
24,
608
],
[
608,
23,
651
]
],
[
[
1184,
24,
1250
],
[
1250,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clin... |
DB01233 | DB01589 | 1,311 | 481 | [
"DDInter1197",
"DDInter1552"
] | Metoclopramide | Quazepam | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
1311,
24,
481
]
],
[
[
1311,
63,
1216
],
[
1216,
1,
481
]
],
[
[
1311,
63,
905
],
[
905,
40,
481
]
],
[
[
1311,
21,
28705
],
[
28705,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound... |
DB00970 | DB00987 | 0 | 1,224 | [
"DDInter466",
"DDInter460"
] | Dactinomycin | Cytarabine | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Moderate | 1 | [
[
[
0,
24,
1224
]
],
[
[
0,
18,
1918
],
[
1918,
46,
1224
]
],
[
[
0,
7,
4698
],
[
4698,
46,
1224
]
],
[
[
0,
18,
5218
],
[
5218,
57,... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Dactinomycin",
"{u} (Compound) downregulates {v} (Gene)",
"PCNA"
],
[
"PCNA",
"{u} (Gene) is upregulated by {v... | Dactinomycin (Compound) downregulates PCNA (Gene) and PCNA (Gene) is upregulated by Cytarabine (Compound)
Dactinomycin (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Cytarabine (Compound)
Dactinomycin (Compound) downregulates UBE2C (Gene) and UBE2C (Gene) is downregulated by Cytarabine (Compound)
... |
DB00472 | DB11978 | 758 | 124 | [
"DDInter758",
"DDInter822"
] | Fluoxetine | Glasdegib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
758,
24,
124
]
],
[
[
758,
23,
112
],
[
112,
23,
124
]
],
[
[
758,
63,
475
],
[
475,
24,
124
]
],
[
[
758,
24,
688
],
[
688,
24,... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Fluoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphin... |
DB00655 | DB01217 | 559 | 630 | [
"DDInter682",
"DDInter95"
] | Estrone | Anastrozole | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantag... | Moderate | 1 | [
[
[
559,
24,
630
]
],
[
[
559,
10,
11579
],
[
11579,
44,
630
]
],
[
[
559,
6,
6017
],
[
6017,
45,
630
]
],
[
[
559,
21,
28921
],
[
28921,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anastrozole"
]
],
[
[
"Estrone",
"{u} (Compound) palliates {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treate... | Estrone (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Anastrozole (Compound)
Estrone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Anastrozole (Compound)
Estrone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Anastrozole (Compou... |
DB00835 | DB01452 | 100 | 993 | [
"DDInter245",
"DDInter532"
] | Brompheniramine | Diamorphine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
100,
24,
993
]
],
[
[
100,
63,
421
],
[
421,
40,
993
]
],
[
[
100,
63,
475
],
[
475,
25,
993
]
],
[
[
100,
63,
13
],
[
13,
24,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threa... |
DB00488 | DB11793 | 196 | 738 | [
"DDInter57",
"DDInter1297"
] | Altretamine | Niraparib | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
196,
24,
738
]
],
[
[
196,
63,
1253
],
[
1253,
24,
738
]
],
[
[
196,
24,
496
],
[
496,
24,
738
]
],
[
[
196,
25,
770
],
[
770,
2... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine ... |
DB00046 | DB00575 | 1,179 | 1,020 | [
"DDInter940",
"DDInter412"
] | Insulin lispro | Clonidine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
1179,
24,
1020
]
],
[
[
1179,
24,
433
],
[
433,
63,
1020
]
],
[
[
1179,
24,
590
],
[
590,
24,
1020
]
],
[
[
1179,
23,
274
],
[
274,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohex... |
DB00153 | DB00564 | 1,331 | 1,236 | [
"DDInter662",
"DDInter293"
] | Ergocalciferol | Carbamazepine | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
1331,
24,
1236
]
],
[
[
1331,
24,
362
],
[
362,
1,
1236
]
],
[
[
1331,
24,
1335
],
[
1335,
40,
1236
]
],
[
[
1331,
6,
8374
],
[
8374,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Carbama... |
DB06779 | DB08822 | 365 | 911 | [
"DDInter470",
"DDInter156"
] | Dalteparin | Azilsartan medoxomil | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
365,
24,
911
]
],
[
[
365,
63,
217
],
[
217,
1,
911
]
],
[
[
365,
64,
1061
],
[
1061,
24,
911
]
],
[
[
365,
25,
802
],
[
802,
24... | [
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
]... | Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Dalteparin may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil may cause a moderate interaction that could ... |
DB00328 | DB00795 | 831 | 50 | [
"DDInter921",
"DDInter1725"
] | Indomethacin | Sulfasalazine | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
831,
24,
50
]
],
[
[
831,
24,
712
],
[
712,
1,
50
]
],
[
[
831,
10,
11591
],
[
11591,
44,
50
]
],
[
[
831,
6,
15333
],
[
15333,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Indomethacin (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Sulfasalazine (Compound)
Indomethacin... |
DB00350 | DB04899 | 1,214 | 1,549 | [
"DDInter1226",
"DDInter1282"
] | Minoxidil | Nesiritide | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide. | Moderate | 1 | [
[
[
1214,
24,
1549
]
],
[
[
1214,
24,
1344
],
[
1344,
63,
1549
]
],
[
[
1214,
24,
1053
],
[
1053,
24,
1549
]
],
[
[
1214,
24,
1344
],
[
13... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nesiritide"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nesiritide
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and ... |
DB05316 | DB11986 | 749 | 484 | [
"DDInter1467",
"DDInter648"
] | Pimavanserin | Entrectinib | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
749,
24,
484
]
],
[
[
749,
62,
112
],
[
112,
23,
484
]
],
[
[
749,
24,
774
],
[
774,
24,
484
]
],
[
[
749,
63,
1674
],
[
1674,
2... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and ... |
DB08881 | DB11110 | 868 | 603 | [
"DDInter1925",
"DDInter1115"
] | Vemurafenib | Magnesium citrate | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
868,
24,
603
]
],
[
[
868,
64,
57
],
[
57,
24,
603
]
],
[
[
868,
25,
484
],
[
484,
63,
603
]
],
[
[
868,
25,
1228
],
[
1228,
24,... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Vemurafenib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Vemurafenib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib ma... |
DB00331 | DB01284 | 1,645 | 1,042 | [
"DDInter1164",
"DDInter1782"
] | Metformin | Tetracosactide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
1645,
24,
1042
]
],
[
[
1645,
24,
455
],
[
455,
23,
1042
]
],
[
[
1645,
24,
659
],
[
659,
62,
1042
]
],
[
[
1645,
24,
811
],
[
811,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilant... |
DB00939 | DB11817 | 1,338 | 1,259 | [
"DDInter1135",
"DDInter165"
] | Meclofenamic acid | Baricitinib | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
1338,
24,
1259
]
],
[
[
1338,
63,
1274
],
[
1274,
24,
1259
]
],
[
[
1338,
24,
1479
],
[
1479,
24,
1259
]
],
[
[
1338,
74,
1512
],
[
15... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Ac... |
DB04845 | DB11988 | 309 | 270 | [
"DDInter1001",
"DDInter1321"
] | Ixabepilone | Ocrelizumab | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
309,
24,
270
]
],
[
[
309,
63,
1461
],
[
1461,
23,
270
]
],
[
[
309,
24,
1060
],
[
1060,
63,
270
]
],
[
[
309,
63,
134
],
[
134,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and... |
DB00544 | DB00754 | 970 | 157 | [
"DDInter757",
"DDInter696"
] | Fluorouracil | Ethotoin | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
970,
24,
157
]
],
[
[
970,
18,
1954
],
[
1954,
57,
157
]
],
[
[
970,
21,
28763
],
[
28763,
60,
157
]
],
[
[
970,
24,
663
],
[
663,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Fluorouracil",
"{u} (Compound) downregulates {v} (Gene)",
"COG2"
],
[
"COG2",
"{u} (Gene) is downregulated by {v... | Fluorouracil (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Ethotoin (Compound)
Fluorouracil (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Ethotoin (Compound)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Met... |
DB01118 | DB09098 | 33 | 98 | [
"DDInter76",
"DDInter1700"
] | Amiodarone | Somatrem | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
33,
24,
98
]
],
[
[
33,
63,
608
],
[
608,
23,
98
]
],
[
[
33,
24,
159
],
[
159,
63,
98
]
],
[
[
33,
64,
11
],
[
11,
24,
98... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrect... |
DB00366 | DB00472 | 1,594 | 758 | [
"DDInter600",
"DDInter758"
] | Doxylamine | Fluoxetine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
1594,
24,
758
]
],
[
[
1594,
24,
358
],
[
358,
1,
758
]
],
[
[
1594,
40,
11296
],
[
11296,
1,
758
]
],
[
[
1594,
24,
109
],
[
109,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Fluoxetine (Compound)
Doxylamine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Fluoxetine (Compound)
Doxylamine may cause a m... |
DB00574 | DB01255 | 121 | 633 | [
"DDInter717",
"DDInter1078"
] | Fenfluramine | Lisdexamfetamine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Major | 2 | [
[
[
121,
25,
633
]
],
[
[
121,
25,
551
],
[
551,
1,
633
]
],
[
[
121,
64,
80
],
[
80,
40,
633
]
],
[
[
121,
64,
1494
],
[
1494,
24,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
... | Fenfluramine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfetamine (Compound)
Fenfluramine... |
DB01105 | DB04896 | 222 | 901 | [
"DDInter1665",
"DDInter1220"
] | Sibutramine | Milnacipran | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
222,
25,
901
]
],
[
[
222,
25,
41
],
[
41,
1,
901
]
],
[
[
222,
64,
1349
],
[
1349,
40,
901
]
],
[
[
222,
6,
6112
],
[
6112,
45,... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",... | Sibutramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Sibutramine (Com... |
DB00341 | DB06700 | 1,242 | 643 | [
"DDInter343",
"DDInter511"
] | Cetirizine | Desvenlafaxine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1242,
24,
643
]
],
[
[
1242,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1242,
21,
28641
],
[
28641,
60,
643
]
],
[
[
1242,
24,
1311
],
[
1311... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Cetirizine (Compound) causes Hot flush (Side Effect) and Hot flush (Side Effect) is caused by Desvenlafaxine (Compound)
Cetirizine may cause a moderate in... |
DB00420 | DB01064 | 508 | 1,148 | [
"DDInter1532",
"DDInter987"
] | Promazine | Isoprenaline | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
508,
24,
1148
]
],
[
[
508,
24,
480
],
[
480,
24,
1148
]
],
[
[
508,
18,
6929
],
[
6929,
57,
1148
]
],
[
[
508,
24,
167
],
[
167,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Promazine (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Isoprenaline (Compound)
Pr... |
DB00342 | DB01100 | 1,181 | 1,568 | [
"DDInter1770",
"DDInter1470"
] | Terfenadine | Pimozide | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
1181,
25,
1568
]
],
[
[
1181,
25,
78
],
[
78,
40,
1568
]
],
[
[
1181,
23,
112
],
[
112,
23,
1568
]
],
[
[
1181,
24,
455
],
[
455,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} (... | Terfenadine may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical ... |
DB00364 | DB00618 | 417 | 1,572 | [
"DDInter1717",
"DDInter498"
] | Sucralfate | Demeclocycline | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Moderate | 1 | [
[
[
417,
24,
1572
]
],
[
[
417,
24,
1620
],
[
1620,
1,
1572
]
],
[
[
417,
63,
964
],
[
964,
1,
1572
]
],
[
[
417,
24,
1669
],
[
1669,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycli... |
DB00675 | DB11642 | 888 | 938 | [
"DDInter1744",
"DDInter1480"
] | Tamoxifen | Pitolisant | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
888,
24,
938
]
],
[
[
888,
23,
112
],
[
112,
23,
938
]
],
[
[
888,
24,
760
],
[
760,
24,
938
]
],
[
[
888,
63,
600
],
[
600,
24,... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobici... |
DB00491 | DB08912 | 127 | 1,040 | [
"DDInter1217",
"DDInter462"
] | Miglitol | Dabrafenib | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
127,
24,
1040
]
],
[
[
127,
6,
8814
],
[
8814,
46,
1040
]
],
[
[
127,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
127,
63,
168
],
[
168,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Miglitol",
"{u} (Compound) binds {v} (Gene)",
"GAA"
],
[
"GAA",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Miglitol (Compound) binds GAA (Gene) and GAA (Gene) is upregulated by Dabrafenib (Compound)
Miglitol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and ... |
DB00736 | DB09280 | 660 | 1,604 | [
"DDInter676",
"DDInter1101"
] | Esomeprazole | Lumacaftor | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
660,
24,
1604
]
],
[
[
660,
1,
379
],
[
379,
24,
1604
]
],
[
[
660,
23,
1468
],
[
1468,
24,
1604
]
],
[
[
660,
64,
1195
],
[
1195,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a m... | Esomeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that cou... |
DB00782 | DB00836 | 1,123 | 543 | [
"DDInter1535",
"DDInter1088"
] | Propantheline | Loperamide | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1123,
24,
543
]
],
[
[
1123,
24,
704
],
[
704,
40,
543
]
],
[
[
1123,
63,
675
],
[
675,
24,
543
]
],
[
[
1123,
40,
11241
],
[
11241,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Loperamide (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate inte... |
DB00501 | DB01206 | 752 | 37 | [
"DDInter380",
"DDInter1086"
] | Cimetidine | Lomustine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Major | 2 | [
[
[
752,
25,
37
]
],
[
[
752,
6,
8374
],
[
8374,
45,
37
]
],
[
[
752,
21,
28722
],
[
28722,
60,
37
]
],
[
[
752,
23,
697
],
[
697,
2... | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomustin... | Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Cimetidine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbit... |
DB00938 | DB06288 | 455 | 607 | [
"DDInter1635",
"DDInter77"
] | Salmeterol | Amisulpride | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Moderate | 1 | [
[
[
455,
24,
607
]
],
[
[
455,
21,
29232
],
[
29232,
60,
607
]
],
[
[
455,
63,
1559
],
[
1559,
24,
607
]
],
[
[
455,
62,
870
],
[
870,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is cau... | Salmeterol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amisul... |
DB00191 | DB08918 | 73 | 41 | [
"DDInter1447",
"DDInter1059"
] | Phentermine | Levomilnacipran | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Major | 2 | [
[
[
73,
25,
41
]
],
[
[
73,
25,
901
],
[
901,
40,
41
]
],
[
[
73,
24,
1349
],
[
1349,
40,
41
]
],
[
[
73,
6,
6112
],
[
6112,
45,
... | [
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
... | Phentermine may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Levomilnacipran (Compound)
P... |
DB00924 | DB12130 | 1,405 | 1,017 | [
"DDInter454",
"DDInter1094"
] | Cyclobenzaprine | Lorlatinib | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1405,
24,
1017
]
],
[
[
1405,
40,
888
],
[
888,
24,
1017
]
],
[
[
1405,
63,
629
],
[
629,
24,
1017
]
],
[
[
1405,
24,
214
],
[
214,
... | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a... | Cyclobenzaprine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that... |
DB04953 | DB06603 | 495 | 39 | [
"DDInter708",
"DDInter1387"
] | Ezogabine | Panobinostat | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
495,
25,
39
]
],
[
[
495,
62,
112
],
[
112,
23,
39
]
],
[
[
495,
63,
272
],
[
272,
24,
39
]
],
[
[
495,
24,
850
],
[
850,
63,
... | [
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB01045 | DB09075 | 463 | 498 | [
"DDInter1590",
"DDInter621"
] | Rifampicin | Edoxaban | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
463,
25,
498
]
],
[
[
463,
25,
1017
],
[
1017,
63,
498
]
],
[
[
463,
24,
129
],
[
129,
24,
498
]
],
[
[
463,
24,
738
],
[
738,
6... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may... | Rifampicin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may caus... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.